Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Allergol Int ; 63(3): 457-66, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24851949

RESUMO

BACKGROUND: Rapamycin has been reported to inhibit mesenchymal cell proliferation in a murine model of pulmonary fibrosis. In the present study, we examined the effects of rapamycin on vascular remodeling including intraluminal myofibroblast proliferation in a murine model of allergic vasculitis with eosinophil infiltration. METHODS: C57BL/6 mice were sensitized with ovalbumin (OVA) and alum. The positive controls were exposed to aerosolized OVA daily for 7 days. The other group of mice was administered with rapamycin (1mg/kg) intraperitoneally, in parallel with daily exposure to aerosolized OVA for 7 days. On the 3rd and 7th day, bronchoalveolar lavage (BAL) was performed and the lungs were excised for pathological analysis. Cell differentials were determined and concentrations of IL-4, IL-5, IL-13 and TGF-ß in the BAL fluid (BALF) were measured. Semi-quantitative analysis of pathological changes in the pulmonary arteries was evaluated according to the severity of vasculitis. RESULTS: The number of eosinophils in BALF was reduced significantly in the mice treated with rapamycin compared to the positive control. There was a significant decrease in the TGF-ß concentration of the BALF in the rapamycin-treated group compared to that of the positive control. The pathological scores were reduced significantly in the rapamycin-treated group compared to the positive control group. Intraluminal myofibroblasts in pulmonary arteries were reduced dramatically in the rapamycin-treated group compared to the positive control group. CONCLUSIONS: Rapamycin suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis with eosinophil infiltration through reducing eosinophil infiltration and TGF-ß production in the lung and inhibition against biological action of TGF-ß.


Assuntos
Hipersensibilidade/tratamento farmacológico , Imunossupressores/administração & dosagem , Pneumopatias/tratamento farmacológico , Artéria Pulmonar/efeitos dos fármacos , Sirolimo/administração & dosagem , Fator de Crescimento Transformador beta/metabolismo , Remodelação Vascular/efeitos dos fármacos , Vasculite/tratamento farmacológico , Animais , Proliferação de Células/efeitos dos fármacos , Modelos Animais de Doenças , Progressão da Doença , Eosinófilos/efeitos dos fármacos , Eosinófilos/patologia , Feminino , Humanos , Hipersensibilidade/imunologia , Pneumopatias/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Miofibroblastos/efeitos dos fármacos , Miofibroblastos/fisiologia , Artéria Pulmonar/patologia , Vasculite/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA